 LA JOLLA, Calif.--BUSINESS WIRE--DermTech, Inc. NASDAQ: DMTK DermTech, a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the topline results from its TRUST Study of the companys non-invasive melanoma rule-out test, the Pigmented Lesion Assay the PLA. The TRUST study is a long-term follow-up study of pigmented skin lesions that tested negative for melanoma with the PLA. It was designed to assess long-term outcomes of PLA negative tes 